Compass Therapeutics (CMPX) Accumulated Expenses: 2023-2025
Historic Accumulated Expenses for Compass Therapeutics (CMPX) over the last 3 years, with Sep 2025 value amounting to $8.7 million.
- Compass Therapeutics' Accumulated Expenses rose 197.81% to $8.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.7 million, marking a year-over-year increase of 197.81%. This contributed to the annual value of $6.3 million for FY2024, which is 150.08% up from last year.
- Latest data reveals that Compass Therapeutics reported Accumulated Expenses of $8.7 million as of Q3 2025, which was down 21.00% from $11.0 million recorded in Q2 2025.
- Over the past 5 years, Compass Therapeutics' Accumulated Expenses peaked at $13.2 million during Q1 2025, and registered a low of $1.8 million during Q1 2024.
- Its 3-year average for Accumulated Expenses is $6.9 million, with a median of $7.2 million in 2024.
- As far as peak fluctuations go, Compass Therapeutics' Accumulated Expenses slumped by 79.70% in 2024, and later skyrocketed by 628.04% in 2025.
- Quarterly analysis of 3 years shows Compass Therapeutics' Accumulated Expenses stood at $2.5 million in 2023, then skyrocketed by 150.08% to $6.3 million in 2024, then skyrocketed by 197.81% to $8.7 million in 2025.
- Its Accumulated Expenses stands at $8.7 million for Q3 2025, versus $11.0 million for Q2 2025 and $13.2 million for Q1 2025.